Dr. Hofmeister Discusses Checkpoint Inhibitors in Myeloma
Craig Hofmeister, MD
Craig Hofmeister, MD, associate professor, The Ohio State University Comprehensive Cancer Center, discusses checkpoint inhibitors in multiple myeloma.
A trial of durvalumab (Imfinzi) and lenalidomide (Revlimid) with and without low-dose dexamethasone in patients with newly diagnosed multiple myeloma, and three other studies exploring durvalumab in multiple myeloma—MEDI4736-MM-001, MEDI4736-MM-003, and MEDI4736-MM-005—were placed on partial hold earlier in 2017.
Hofmeister hopes that with further testing they will be incorporated as relapsed, and ultimately upfront therapy for patients with multiple myeloma.